Sexual function in elderly men receiving Androgen Deprivation Therapy (ADT)

Sexual Medicine Reviews

Volumn 2, Issue 1, 2014, Pages 36-46

  Fode, Mikkel ^a   Sønksen, Jens ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Androgen Deprivation Therapy; Erectile Function; Prostatic Neoplasms; Quality of Life; Sexual Function; Side Effects

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; HUMAN; INTIMACY; MAJOR CLINICAL STUDY; MALE; MASCULINITY; PENIS PROSTHESIS; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL COUNSELING; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL PRACTICE; UROLOGICAL THERAPEUTIC DEVICE; VACUUM ERECTION DEVICE;

EID: 84908522498     PISSN: 20500513     EISSN: 20500521     Source Type: Journal    
DOI: 10.1002/smrj.17     Document Type: Review

References (100)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int 2011;108:1734-1738.
3. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-583.
4. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-1721.
5. McLeod DG. Hormonal therapy: Historical perspective to future directions. Urology 2003;61(1 suppl):3-7.
6. Khan MS, O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 1998;60:33-40.
7. Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: Pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001;10:709-720.
8. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743-1746.
9. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealey GT. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992;1:323-329.
10. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE, Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997;49:207-216.
11. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
12. Gades NM, Jacobson DJ, McGree ME, St Sauver JL, Lieber MM, Nehra A, Girman CJ, Klee GG, Jacobsen SJ. The associations between serum sex hormones, erectile function, and sex drive: The Olmsted County Study of Urinary Symptoms and Health Status among Men. J Sex Med 2008;5:2209-2220.
13. Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, Brahler E, Weidner W. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005;47:749-755.
14. Rhoden EL, Teloken C, Mafessoni R, Souto CA. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction? Int J Impot Res 2002;14:167-171.
15. Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. J Urol 2006;176(Pt 1):2584-2588.
16. Marberger M, Wilson TH, Rittmaster RS. Low serum testosterone levels are poor predictors of sexual dysfunction. BJU Int 2011;108:256-262.
17. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: A combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983;57:557-562.
18. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
19. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
20. Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2002;14(1 suppl):S6-10.
21. Maggi M, Filippi S, Ledda F, Magini A, Forti G. Erectile dysfunction: From biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 2000;143:143-154.
22. Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, Huang YH, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24:381-387.
23. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: A potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005;26:242-248.
24. Takahashi Y, Hirata Y, Yokoyama S, Ishii N, Nunes L, Lue TF, Tanagho EA. Loss of penile erectile response to intracavernous injection of acetylcholine in castrated dog. Tohoku J Exp Med 1991;163:85-91.
25. Hwang EC, Oh KJ, Jung SI, Kim NN, Ahn KY, Park K. Effects of androgen on the expression of vascular endothelial growth factor in the penile corpus cavernosum. Urology 2011;77:1381-1386.
26. Armagan A, Hatsushi K, Toselli P. The effects of testosterone deficiency on the structural integrity of the penile dorsal nerve in the rat. Int J Impot Res 2008;20:73-78.
27. Suzuki N, Sato Y, Hisasue S, Kato R, Suzuki K, Tsukamoto T. Effect of testosterone on intracavernous pressure elicited with electrical stimulation of the medial preoptic area and cavernous nerve in male rats. J Androl 2007;28:218-222.
28. Giuliano F, Rampin O, Schirar A, Jardin A, Rousseau JP. Autonomic control of penile erection: Modulation by testosterone in the rat. J Neuroendocrinol 1993;5:677-683.
29. Baba K, Yajima M, Carrier S, Akkus E, Reman J, Nunes L, Lue TF, Iwamoto T. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology 2000;56:533-538.
30. Bialy M, Nikolaev-Diak A, Kalata U, Nikolaev E. Blockade of androgen receptor in the medial amygdala inhibits noncontact erections in male rats. Physiol Behav 2011;103:295-301.
31. Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 1993;91:437-442.
32. Moreland RB. Is there a role of hypoxemia in penile fibrosis: A viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 1998;10:113-120.
33. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, Krane RJ, Udelson D, Saenz de Tejada I, Moreland RB. Mechanisms of venous leakage: A prospective clinicopathological correlation of corporeal function and structure. J Urol 1996;156:1320-1329.
34. Aucoin MW, Wassersug RJ. The sexuality and social performance of androgen-deprived (castrated) men throughout history: Implications for modern day cancer patients. Soc Sci Med 2006;63:3162-3173.
35. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: A rat erection model. Int J Impot Res 1995;7:209-219.
36. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl 1997;18:110-115.
37. Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999;61:1012-1016.
38. Schirar A, Bonnefond C, Meusnier C, Devinoy E. Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology 1997;138:3093-3102.
39. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-416.
40. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-2263.
41. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-99.
42. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571-574.
43. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-638.
44. Hirshkowitz M, Moore CA, O'Connor S, Bellamy M, Cunningham GR. Androgen and sleep-related erections. J Psychosom Res 1997;42:541-546.
45. Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A. Androgens and penile erection: Evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:517-522.
46. Haliloglu A, Baltaci S, Yaman O. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol 2007;177:128-130.
47. Park KK, Lee SH, Chung BH. The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: A single-center, prospective, open-label, observational study. J Sex Med 2011;8:3214-3219.
48. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports. J Sex Med 2006;3:727-735.
49. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC. Age-related changes in general and sexual health in middle-aged and older men: Results from the European Male Ageing Study (EMAS). J Sex Med 2010;7(Pt 1):1362-1380.
50. Incrocci L, Madalinska JB, Essink-Bot ML, Van Putten WL, Koper PC, Schroder FH. Sexual functioning in patients with localized prostate cancer awaiting treatment. J Sex Marital Ther 2001;27:353-363.
51. Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: A meta-analysis. J Sex Med 2009;6:2538-2546.
52. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol 2012;61:112-127.
53. Bergman B, Damber JE, Littbrand B, Sjogren K, Tomic R. Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy or oestrogens. Br J Urol 1984;56:64-69.
54. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-786.
55. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002;11:401-414.
56. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-437.
57. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999;6:19-23.
58. Fowler FJ, Jr, McNaughton CM, Walker CE, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287-295.
59. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-1242.
60. Mazzola CR, Deveci S, Heck M, Mulhall JP. Androgen deprivation therapy before radical prostatectomy is associated with poorer postoperative erectile function outcomes. BJU Int 2012;110:112-116.
61. Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007;178:2521-2525.
62. Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav 1988;17:87-98.
63. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-3757.
64. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003;97:1653-1662.
65. Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol 1995;153(Pt 1):650-652.
66. Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Steineck G. Factors associated with waning sexual function among elderly men and prostate cancer patients. J Urol 1997;158:155-159.
67. Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: Observations from a prospective study in men undergoing intermittent androgen suppression. J Urol 2012;187:2162-2166.
68. Soloway CT, Soloway MS, Kim SS, Kava BR. Sexual, psychological and dyadic qualities of the prostate cancer "couple." BJU Int 2005;95:780-785.
69. Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl 2012;14:198-203.
70. Meuleman EJ, van Lankveld JJ. Hypoactive sexual desire disorder: An underestimated condition in men. BJU Int 2005;95:291-296.
71. Litwin MS, Shpall AI, Dorey F, Nguyen TH. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998;21:327-332.
72. Navon L, Morag A. Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties. Qual Health Res 2003;13:1378-1392.
73. Klaeson K, Sandell K, Bertero CM. Sexuality in the context of prostate cancer narratives. Qual Health Res 2012;22:1184-1194.
74. DiBlasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG, Patterson AL, Wake RW, Derweesh IH. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 2008;15:4249-4256.
75. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA. Sexuality after treatment for early prostate cancer: Exploring the meanings of "erectile dysfunction." J Gen Intern Med 2001;16:649-655.
76. Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, Spaulding M, Talcott JA. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21:3777-3784.
77. Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 2011;185:17-23.
78. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58:139-146.
79. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 2010;57:49-59.
80. Malone S, Perry G, Segal R, Dahrouge S, Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: Results of a phase II study. BJU Int 2005;96:514-520.
81. Klotz L. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr Urol Rep 2013;14:159-167.
82. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van PH, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-1582.
83. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51:306-313.
84. Katz A. The sounds of silence: Sexuality information for cancer patients. J Clin Oncol 2005;23:238-241.
85. Boberg EW, Gustafson DH, Hawkins RP, Offord KP, Koch C, Wen KY, Kreutz K, Salner A. Assessing the unmet information, support and care delivery needs of men with prostate cancer. Patient Educ Couns 2003;49:233-242.
86. McCabe MP, Conaglen H, Conaglen J, O'Connor E. Motivations for seeking treatment for ED: The woman's perspective. Int J Impot Res 2010;22:152-158.
87. Hagedoorn M, Sanderman R, Bolks HN, Tuinstra J, Coyne JC. Distress in couples coping with cancer: A meta-analysis and critical review of role and gender effects. Psychol Bull 2008;134:1-30.
88. Walker LM, Robinson JW. A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer. Psychooncology 2011;20:880-888.
89. Crowe H, Costello AJ. Prostate cancer: Perspectives on quality of life and impact of treatment on patients and their partners. Urol Nurs 2003;23:279-285.
90. Cayan S, Bozlu M, Canpolat B, Akbay E. The assessment of sexual functions in women with male partners complaining of erectile dysfunction: Does treatment of male sexual dysfunction improve female partner's sexual functions? J Sex Marital Ther 2004;30:333-341.
91. Shindel A, Quayle S, Yan Y, Husain A, Naughton C. Sexual dysfunction in female partners of men who have undergone radical prostatectomy correlates with sexual dysfunction of the male partner. J Sex Med 2005;2:833-841.
92. Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010;36:154-165.
93. Wittmann D, Northouse L, Foley S, Gilbert S, Wood DP, Jr, Balon R, Montie JE. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res 2009;21:99-106.
94. Ahmadi H, Daneshmand S. Androgen deprivation therapy: Evidence-based management of side effects. BJU Int 2013;111:543-548.
95. DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008;102:39-43.
96. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
97. Watkins BD, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: Results of RTOG 0215. J Sex Med 2011;8:1228-1238.
98. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life. J Sex Med 2010;7:2996-3010.
99. Oliffe J. Constructions of masculinity following prostatectomy-induced impotence. Soc Sci Med 2005;60:2249-2259.
100. Lemieux L, Kaiser S, Pereira J, Meadows LM. Sexuality in palliative care: Patient perspectives. Palliat Med 2004;18:630-637.